Leqembi

Lecanemab, the active ingredient in Leqembi, is a monoclonal antibody presented as an intravenous solution for intravenous use. It is indicated for the treatment of Alzheimer’s disease in patients with early symptomatic disease, where it targets soluble aggregated amyloid‑beta protofibrils to reduce plaque burden and modify disease progression.

GNH USA supplies Leqembi as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. Our distribution network ensures regulatory‑aligned delivery and cold‑chain handling where required, supporting patients across multiple regions.

Leqembi is an amyloid‑beta‑directed disease‑modifying therapy used in Alzheimer’s disease.

Alzheimer’s disease (early symptomatic): slows cognitive and functional decline in eligible patients. Mild cognitive impairment due to Alzheimer’s disease: reduces amyloid plaque burden and may delay progression. Early‑stage Alzheimer’s disease: modifies disease trajectory by clearing soluble aggregated amyloid‑beta protofibrils.

Leqembi may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Infusion‑related reactions (e.g., flushing, chills, rash) - Headache - Dizziness - Nausea - Peripheral edema - Arthralgia

Serious or Rare Side Effects: - Amyloid‑related imaging abnormalities (ARIA), including edema or microhemorrhage - Severe hypersensitivity or anaphylaxis - Encephalitis - Thrombocytopenia - Severe infusion reactions requiring medical intervention

Prior to initiating therapy, clinicians should consider several safety measures.

Assess renal function: monitor patients with impaired renal clearance. Screen for ARIA: obtain baseline MRI and follow‑up imaging as recommended. Monitor for infusion reactions: have emergency medications and equipment ready during administration. Avoid use in patients with known hypersensitivity to lecanemab or any excipients. Pregnancy and lactation: prescribe only if potential benefits justify potential risks. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Leqembi can interact with other therapies; awareness of interaction severity guides clinical decisions.

Major Interactions (Avoid): - Concurrent use with other amyloid‑targeting antibodies: increased risk of ARIA. - Strong immunosuppressants: may alter immune response to the monoclonal antibody. - Live vaccines: reduced efficacy and potential safety concerns.

Moderate Interactions (Monitor Closely): - Anticoagulants or antiplatelet agents: monitor for bleeding if ARIA occurs. - Other monoclonal antibodies: watch for additive infusion‑related reactions. - CYP450 substrates: minimal interaction but observe for unexpected pharmacodynamic changes.